A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous for F508del and a Gating (F/G) or Residual Function (F/R

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/21 → 5/25/24

Funding

  • Vertex Pharmaceuticals Inc: $134,708.00